Vevye now available in US for treatment of dry eye disease

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.
“We are excited to see Vevye’s exceptional clinical trial data come to life as U.S. dry eye disease patients are now able to access and experience a highly tolerable product that provides rapid onset of relief and sustained improvement of both signs and symptoms of dry eye disease,” Mark L. Baum, chairman and CEO at Harrow, said in the release.
Approved by the FDA

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart